WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406459
Description: Bromosporine is a broad spectrum inhibitor for bromodomains and as such will be very useful in elucidating further biological roles of reader domains as well as a tool for the validation of functional assays. Proteins that contain BRDs have been implicated in the development of a large variety of diseases, including various cancers, inflammatory diseases and neurological diseases and the therapeutic potential of bromodomain inhibition has been shown in several of these diseases, such as HIV, cancer and inflammation.
MedKoo Cat#: 406459
Chemical Formula: C17H20N6O4S
Exact Mass: 404.12667
Molecular Weight: 404.4435
Elemental Analysis: C, 50.48; H, 4.98; N, 20.78; O, 15.82; S, 7.93
IUPAC/Chemical Name: ethyl (3-methyl-6-(4-methyl-3-(methylsulfonamido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-yl)carbamate
InChi Key: UYBRROMMFMPJAN-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H20N6O4S/c1-5-27-17(24)18-15-9-14(21-23-11(3)19-20-16(15)23)12-7-6-10(2)13(8-12)22-28(4,25)26/h6-9,22H,5H2,1-4H3,(H,18,24)
SMILES Code: O=C(OCC)NC1=CC(C2=CC=C(C)C(NS(=O)(C)=O)=C2)=NN3C1=NN=C3C
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
|Biological target:||Bromosporine is a broad spectrum inhibitor for bromodomains with IC50 of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively.|
|In vitro activity:||After treating with 2.5 μM bromosporine for 72h, the percentage of GFP-expressing cells was measured by flow cytometry, which represented the expression of HIV-1 LTR-driven GFP. The percentage of GFP-positive cells increased to 85.6% as compared to mock treatment (Figure 1B). In addition, dose- and time-dependent effects of bromosporine on HIV-1 reactivation were also observed in C11 cells (Figure 1C and 1D) (Supplementary Figure 1). As shown in Figure 1C, the percentage of GFP-positive cells dramatically raised from 6.88% to 87.7% as the concentration of bromosporine increased from 0.1 μM to 2.5 μM. And as shown in Figure Figure1D, after C11 cells were treated with 2.5 μM bromosporine, the percentage of GFP-positive cells increased as a function of time. Reference: Oncotarget. 2017 Nov 7; 8(55): 94104–94116. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706859/|
|In vivo activity:||Following the in vitro effect of 5-FU with bromosporine, the effect of the drugs together as well as individual exposures were studied in the mouse model administered the drugs as described in the materials section. The combinatorial approach was found to inhibit the tumor growth of the HCT116 xenograft against individual drugs (Fig. 4A). This was further confirmed by data from body weight with an absence of higher toxicity (Fig. 4B). Tumor protein analysis revealed that cleaved caspase 3 was significantly increased in combination treatment group (Fig. 4C). These findings show that the synergistic action of the drug combination of bromosporine with 5-FU in vivo. Reference: Biochem Biophys Res Commun. 2020 Jan 22;521(4):840-845. https://pubmed.ncbi.nlm.nih.gov/31708100/|
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO:PBS (pH 7.2) (1:1)||0.5||1.24|
The following data is based on the product molecular weight 404.4435 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
|Formulation protocol:||1. Cheng X, Huang Z, Long D, Jin W. BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells. Biochem Biophys Res Commun. 2020 Jan 22;521(4):840-845. doi: 10.1016/j.bbrc.2019.11.009. Epub 2019 Nov 7. PMID: 31708100. 2. Pan H, Lu P, Shen Y, Wang Y, Jiang Z, Yang X, Zhong Y, Yang H, Khan IU, Zhou M, Li B, Zhang Z, Xu J, Lu H, Zhu H. The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells. Oncotarget. 2017 Oct 6;8(55):94104-94116. doi: 10.18632/oncotarget.21585. PMID: 29212213; PMCID: PMC5706859.|
|In vitro protocol:||1. Cheng X, Huang Z, Long D, Jin W. BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells. Biochem Biophys Res Commun. 2020 Jan 22;521(4):840-845. doi: 10.1016/j.bbrc.2019.11.009. Epub 2019 Nov 7. PMID: 31708100. 2. Pan H, Lu P, Shen Y, Wang Y, Jiang Z, Yang X, Zhong Y, Yang H, Khan IU, Zhou M, Li B, Zhang Z, Xu J, Lu H, Zhu H. The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells. Oncotarget. 2017 Oct 6;8(55):94104-94116. doi: 10.18632/oncotarget.21585. PMID: 29212213; PMCID: PMC5706859.|
|In vivo protocol:||1. Cheng X, Huang Z, Long D, Jin W. BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells. Biochem Biophys Res Commun. 2020 Jan 22;521(4):840-845. doi: 10.1016/j.bbrc.2019.11.009. Epub 2019 Nov 7. PMID: 31708100.|
1: Zdrowowicz M, Chomicz L, Miloch J, Wiczk J, Rak J, Kciuk G, Bobrowski K. Reactivity pattern of bromonucleosides induced by 2-hydroxypropyl radicals: photochemical, radiation chemical, and computational studies. J Phys Chem B. 2015 Jun 4;119(22):6545-54. doi: 10.1021/acs.jpcb.5b01904. Epub 2015 May 26. PubMed PMID: 25971814.
2: Steklov MY, Tararov VI, Romanov GA, Mikhailov SN. Facile synthesis of 8-azido-6-benzylaminopurine. Nucleosides Nucleotides Nucleic Acids. 2011 Jul-Aug;30(7-8):503-11. doi: 10.1080/15257770.2011.602655. PubMed PMID: 21888542.
3: Andrei M, Bjørnstad V, Langli G, Rømming C, Klaveness J, Taskén K, Undheim K. Stereoselective preparation of (RP)-8-hetaryladenosine-3',5'-cyclic phosphorothioic acids. Org Biomol Chem. 2007 Jul 7;5(13):2070-80. Epub 2007 May 29. PubMed PMID: 17581650.
4: Champeil E, Pradhan P, Lakshman MK. Palladium-catalyzed synthesis of nucleoside adducts from bay- and fjord-region diol epoxides. J Org Chem. 2007 Jul 6;72(14):5035-45. Epub 2007 Jun 9. PubMed PMID: 17559269; PubMed Central PMCID: PMC2548296.
5: Dai Q, Xu D, Lim K, Harvey RG. Efficient syntheses of C(8)-aryl adducts of adenine and guanine formed by reaction of radical cation metabolites of carcinogenic polycyclic aromatic hydrocarbons with DNA. J Org Chem. 2007 Jun 22;72(13):4856-63. Epub 2007 May 27. PubMed PMID: 17530898.
6: Russo M, Jimenez LB, Mulazzani QG, D'Angelantonio M, Guerra M, Miranda MA, Chatgilialoglu C. Chemical radiation studies of 8-bromo-2'-deoxyinosine and 8-bromoinosine in aqueous solutions. Chemistry. 2006 Oct 10;12(29):7684-93. PubMed PMID: 16823787.
7: Johnson F, Bonala R, Tawde D, Torres MC, Iden CR. Efficient synthesis of the benzo[a]pyrene metabolic adducts of 2'-deoxyguanosine and 2'-deoxyadenosine and their direct incorporation into DNA. Chem Res Toxicol. 2002 Dec;15(12):1489-94. PubMed PMID: 12482230.
8: Véliz EA, Beal PA. 6-bromopurine nucleosides as reagents for nucleoside analogue synthesis. J Org Chem. 2001 Dec 14;66(25):8592-8. PubMed PMID: 11735542.
9: Janeba Z, Holý A. Synthesis of 8-amino and 8-substituted amino derivatives of acyclic purine nucleoside and nucleotide analogs. Alkylation of 8-substituted purine bases. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1103-6. PubMed PMID: 11562965.
10: Bodepudi V, Shibutani S, Johnson F. Synthesis of 2'-deoxy-7,8-dihydro-8-oxoguanosine and 2'-deoxy-7,8-dihydro-8-oxoadenosine and their incorporation into oligomeric DNA. Chem Res Toxicol. 1992 Sep-Oct;5(5):608-17. PubMed PMID: 1445999.